Table 2 Comparison of DLL3 expression levels and clinicopathological characteristics in neuroendocrine carcinomas by tumor type

From: Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms

Characteristics

Bladder

Head&Neck

Lung*

Uterine cervix**

Skin***

Thyroid****

Prostate

SCC (n = 19)

NEC (n = 19)

NEC (n = 45)

NEC (n = 21)

MCC (n = 33)

MC (n = 74)

SCC (n = 16)

N

%

Median Total H-score

P value

N

%

Median Total H-score

P value

N

%

Median Total H-score

P value

N

%

Median Total H-score

P value

N

%

Median Total H-score

P value

N

%

Median Total H-score

P value

N

%

Median Total H-score

P value

Sex

F

1

5.3

NA

NA

7

36.8

40

0.36

19

42.2

50

0.019

21

100.0

125

NA

8

24.2

150

0.94

34

45.9

0

0.086

0

0.0

NA

NA

 

M

17

89.5

80

11

57.9

7

26

57.8

140

0

0.0

NA

21

63.6

145

37

50.0

0

16

100.0

115

uk

1

5.3

NA

 

1

5.3

NA

 

0

0.0

NA

 

0

0.0

NA

 

4

12.1

50

 

3

4.1

0

 

0

0.0

NA

 

Stage

I/II

8

42.1

38.5

0.52

2

10.5

62

0.67

26

57.8

87.5

0.24

11

52.4

115

0.39

10

30.3

125

0.42

24

32.4

0

0.66

2

12.5

132

0.75

 

III/IV

8

42.1

120

1

5.3

NA

14

31.1

140

7

33.3

125

19

57.6

145

44

59.5

0

10

62.5

118

uk

3

15.8

70

 

16

84.2

8

 

5

11.1

0

 

3

14.3

135

 

4

12.1

50

 

6

8.1

0

 

4

25.0

27.5

 

Previous Treatment

No

9

47.4

70

0.7

18

94.7

12.5

NA

33

73.3

95

0.71

14

66.7

120

0.34

18

54.5

148

0.79

70

94.6

0

NA

0

0.0

NA

NA

 

Yes

8

42.1

87.5

0

0.0

NA

9

20.0

105

2

9.5

7

11

33.3

145

0

0.0

NA

2

12.5

125

uk

2

10.5

100

 

1

5.3

NA

 

3

6.7

40

 

5

23.8

125

 

4

12.1

50

 

4

5.4

0

 

14

87.5

115

 

Recurrence at 5 years

No

8

42.1

97.5

0.6

7

36.8

0

0.067

27

60.0

80

0.47

6

28.6

70.5

0.68

16

48.5

150

0.87

54

73.0

0

0.24

3

18.8

145

0.036

 

Yes

2

10.5

75

7

36.8

55

12

26.7

112

9

42.9

130

12

36.4

145

9

12.2

0

5

31.3

55

uk

9

47.4

70

 

5

26.3

16

 

6

13.3

140

 

6

28.6

118

 

5

15.2

86

 

11

14.9

0

 

8

50.0

118

 

Survival at 5 years

D

15

78.9

70

0.99

12

63.2

47.5

0.21

28

62.2

80

0.87

13

61.9

130

0.86

13

39.4

140

0.24

17

23.0

0

0.66

10

62.5

115

0.33

 

A

2

10.5

85

6

31.6

2

17

37.8

105

6

28.6

130

16

48.5

155

51

68.9

0

6

37.5

125

uk

2

10.5

100

 

1

5.3

NA

 

0

0.0

NA

 

2

9.5

67.5

 

4

12.1

50

 

6

8.1

0

 

0

0.0

NA

 

DLL3 IHC site

M/R

0

0.0

NA

NA

4

21.1

8

0.9

3

6.7

40

0.26

0

0.0

NA

NA

5

15.2

82

0.16

0

0.0

NA

NA

10

62.5

115

0.85

 

P

19

100.0

70

12

63.2

22

42

93.3

100

21

100.0

125

24

72.7

145

72

97.3

0

5

31.3

135

uk

0

0.0

NA

 

3

15.8

16

 

0

0.0

NA

 

0

0.0

NA

 

4

12.1

79

 

2

2.7

0

 

1

6.3

NA

 

Smoking status

C

0

0.0

NA

0.88

1

5.3

NA

0.21

32

71.1

50

0.07

1

4.8

NA

0.56

0

0.0

NA

0.43

3

4.1

0

0.76

2

12.5

82.5

0.73

 

FR

11

57.9

70

6

31.6

7

13

28.9

95

2

9.5

142.7

11

33.3

135

20

27.0

0

5

31.3

140

N

6

31.6

130

7

36.8

16

0

0.0

NA

18

85.7

130

22

66.7

147.5

51

68.9

0

8

50.0

110

uk

2

10.5

100

 

5

26.3

65

 

0

0.0

NA

 

0

0.0

NA

 

0

0.0

NA

 

0

0.0

NA

 

0

0.0

NA

 
  1. SCC small cell carcinoma, NEC neuroendocrine carcinoma, *SCLC Small lung cell carcinoma, LCNEC large cell neuroendocrine carcinoma; and combined histology, **SCNEC small cell neuroendocrine carcinoma, LCNEC large cell neuroendocrine carcinoma; and combined histology, ***MCC Merkel cell carcinoma, ****MC medullary carcinoma, F female, M male, uk unknown, D death, A alive, M/R metastasis or recurrence, P primary, C current, FR former, N never.
Back to article page